Revolution Medicines, Inc. (RVMD): debt financing — Revolution Medicines secures up to $2B financing from Royalty Pharma, withdraws cash runway guidance

Revolution Medicines, Inc.

Received $250M upfront from Royalty Pharma; up to $1.25B total synthetic royalty on daraxonrasib sales.
Loan facility of up to $750M senior secured term loan (SOFR+5.75%, 3.50% floor), interest-only, matures by 2032.
Additional tranches tied to daraxonrasib approval milestones; company retains global commercialization control.
Withdraws prior cash runway end date and 2025 GAAP net loss guidance; expects updated guidance in Q2 2025 earnings.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Revolution Medicines, Inc. incurred debt of $250.0 million with Royalty Pharma Investments 2019 ICAV maturing 15 years after the first commercial sale of RMC-6236 in the United States.

Principal: $250.0 million
Counterparty: Royalty Pharma Investments 2019 ICAV
Maturity: 15 years after the first commercial sale of RMC-6236 in the United States
Event: incurrence

Exact text from the filing

On June 23, 2025 (the “Effective Date”), Revolution Medicines, Inc. (the “Company”) entered into a revenue participation right purchase and sale agreement (the “Royalty Purchase Agreement”) with Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”). Pursuant to the Royalty Purchase Agreement, in exchange for an upfront payment of $250.0 million, Royalty Pharma purchased from the Company the right to receive tiered revenue payments (the “Royalty Payments”) with respect to worldwide net product sales

View on SEC.gov

114 debt financings filed in the last 30 days. Browse all debt financings →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-145242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.